Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the

endocrine therapy
serum calcium
white blood cells
neutrophil count
palbociclib
  • 161 views
  • 08 Nov, 2020
  • 1 location
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2

endocrine therapy
hormone therapy
her2/neu-negative breast cancer
invasive breast cancer
immunostimulant
  • 0 views
  • 07 May, 2020
  • 1 location
Palbociclib In Progressive Brain Metastases

This research study is studying palbociclib as a possible treatment for recurrent brain metastases. Pfizer, a pharmaceutical company, is supporting this research study by

  • 84 views
  • 13 Sep, 2020
  • 2 locations
The Resistance and Immune Response to Palbociclib in Breast Cancer

Breast Cancer (BC) treated with Palbociclib in combination with endocrine therapies.

breast cancer
endocrine therapy
hormone therapy
palbociclib
  • 4 views
  • 08 Nov, 2020
Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

PATRICIA is a phase II, open-label, multicentre, Simon's two-stage-design study of the combination of palbociclib plus trastuzumab, with or without letrozole, in post-menopausal patients with

letrozole
endocrine therapy
breast adenocarcinoma
hormone therapy
chromogenic in situ hybridization
  • 15 views
  • 03 Aug, 2020
  • 23 locations
Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC

The goal of this research study is to determine if the investigators can predict which participants will respond to an aromatase inhibitor and palbociclib for metastatic breast cancer and which

measurable disease
gonadotropin releasing hormone
stage iv breast cancer
aromatase inhibitor
estrogen
  • 12 views
  • 20 Jul, 2020
  • 1 location
Avelumab Cetuximab and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The purpose of the study is to find out if the study drugs Avelumab, Cetuximab, and Palbociclib will slow or stop your cancer from getting worse, and whether it causes side effects. The second

monoclonal antibodies
squamous cell carcinoma
kidney function tests
palbociclib
metastatic head and neck squamous cell carcinoma
  • 1 views
  • 25 Oct, 2020
  • 1 location
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

PROMETEO II is a single-arm window of opportunity trial to evaluate biologic and anti-proliferative effects of palbociclib and letrozole in HR+/HER2-negative operable breast cancer (BC) patients

letrozole
docetaxel
cyclophosphamide
paclitaxel
estradiol
  • 2 views
  • 05 Aug, 2020
  • 5 locations
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

measurable disease
breast cancer
metastatic carcinoma
metastasis
cancer
  • 45 views
  • 17 Jun, 2020
  • 3 locations
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib

  • 0 views
  • 09 Dec, 2020
  • 1 location